Inclusion Criteria:  Age: ≥ 18 years old; NSCLC confirmed by histopathology; According to the doctor's advice, according to the routine diagnosis and treatment process, lung cancer patients who need radical resection and neoadjuvant therapy before operation; No previous treatment for esophageal cancer, including surgery, chemotherapy, radiotherapy, targeted therapy, hormone or immunotherapy; ECoG score was 0 or 1; There was no operative contraindication in preoperative organ function examination; At least 6 months of expected survival  The laboratory examination met the following standards:  Bone marrow function: hemoglobin (HB) ≥ 90g / L; White blood cell count (WBC) ≥ the lower limit of normal value; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L； Platelet count ≥ 90 × 10^9/L； Renal function: Cr ≤ unl (upper limit of normal value) × 5, CCR ≥ 55ml / min; Liver function: total bilirubin ≤ ULN × 1.5； ALT and AST ≤ ULN × 2.5 (patients with liver metastasis can be relaxed to ≤ 5 * ULN); Coagulation function: international normalized ratio of prothrombin time ≤ ULN × 5, and partial thromboplastin time was within the normal range; The subjects agreed and voluntarily signed the informed consent  Exclusion Criteria:  Allergic to the study drug; History of hemorrhagic disease or with hemorrhagic disease Liver and kidney dysfunction; Patients with uncontrolled diseases (including but not limited to: active infection, symptomatic congestive heart failure; Myocardial infarction occurred within 3 months; Unstable angina, arrhythmia, etc.); Women of childbearing age are unwilling to use contraception; Lactating women; For any other reason, the researchers consider it inappropriate to participate in the trial.